the prognostic value of karyotypic complexity in ibrutinib-treated cll patients
Published 3 years ago • 63 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
3:03
the evolution of treatment patterns and prognostic biomarkers in latin american cll patients
-
1:30
the prognostic value of patient-reported outcomes in mds
-
2:02
the prognostic impact of tp53 and ighv status in the era of targeted therapies in cll
-
1:19
the prognostic value of mrd in cll
-
2:38
importance of prognostic factors in the treatment of cll and how to assess them
-
4:22
present value of clbt
-
3:31
present value of clb
-
3:13
cll versus other leukemia types
-
1:11
the prognostic value of ighv mutational status with continuous vs time-limited therapy in cll
-
3:16
prognostic markers for the treatment of cll
-
3:40
are complex karyotypes reliable prognostic markers for cll?
-
4:46
prediction and prognostication methods for cll
-
1:17
relevance of prognostic factors in the era of targeted therapies in cll
-
1:59
the role of mrd as a prognostic & predictive biomarker in cll
-
2:20
adverse prognostic features & treatment response in cll
-
2:08
prognostic value of high-sensitivity mrd assessment in cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
1:18
the epidemiology and treatment of chronic gvhd post-allosct
-
1:14
prognostic markers for cll - how do they help determine who gets which treatment?
-
3:04
are prognostic factors the key to precision medicine in cll?
-
1:05
the prognostic and potentially therapeutic value of liquid biopsy in multiple myeloma
-
1:43
the use of cll-ipi, a new prognostic index for cll